 Response oral leukoplakia beta-carotene Leukoplakia increased risk oral cancer premalignant lesion Retinoids retinoic acid leukoplakia drugs considerable toxicity suitable large-scale use prevention oral cancer Beta-carotene nontoxic carotenoid biologic properties efficacious oral leukoplakia randomized study retinoic acid mg/kg/d beta-carotene mg/d leukoplakia marked differences toxicity compounds consent form initial eligible patients beta-carotene study design phase II trial beta-carotene compound months patients months treatment lesions entry Responses bidimensional measurements photography entry treatment study completion Twenty-four evaluable patients major responses complete partial response rate confidence limits significant toxicity drug discontinuation dose reduction results beta-carotene substantial activity oral premalignancy lack toxicity excellent candidate preventive agent oral cancer